LTBR and neoplasm: Interestingly, the treatment of immunotherapy-resistant Ag104Ld tumors with Ab-LIGHT (homologous to lymphotoxin)-based therapy can activate the lymphotoxin β receptor (LTβR) signaling specifically in tumor cells which is leading to enhanced secretion of multiple chemokines.